CliffBio
biologic

Nucala

mepolizumab

Loss of exclusivityJanuary 2034projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →View the full company profile on CliffBio

Drug detail

Brand nameNucala
Active ingredientmepolizumab
Strength40MG/0.4ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2022
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nucala patent cliff — loss of exclusivity January 2034 | CliffBio